Latest News and Press Releases

Parsippany, NJ, May 13, 2026 (GLOBE NEWSWIRE) -- The Lincoln Foundation for Education Inc. (LiFE), a nonprofit 501(c)(3) organization, received nearly a quarter of a million dollars in first‑quarter...

PharmAla announces signed definitive agreement to form a special purpose vehicle to spin out APA-01 entity for development, partnering with Diteba

MITOLINE®-Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development Neve Yarak, Israel, May 13, 2026 (GLOBE NEWSWIRE) --...

- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer -  - First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in...

Total product sales of €30.5 million Cash position of €105.3 million as of end March 2026, excluding proceeds from successful reserved offering completed in April 20261Program launched in April to...

Ventes de produits de 30,5 millions d’euros Position de trésorerie de 105,3 millions d’euros à fin mars 2026, hors produit de la levée de fonds réservée réalisée avec succès en avril 20261Lancement,...

GREELEY, Colo., May 12, 2026 (GLOBE NEWSWIRE) -- JBS reported net revenue of US$21.6 billion in 1Q26, an increase of 11% compared to 1Q25. Net income totaled US$221 million from January through...

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) and...

Next anticipated Revita® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing for...

REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all...